Igenica Header
  | | | | |

 

Igenica Management
David V. Goeddel, Ph.D.
Executive Chairman
John K. Celebi, MBA Chief Business Officer
Guoqing Chen, Ph.D. VP of Research
Paul W. Sauer, MBA VP of Process Development
Igenica Management
David V. Goeddel, Ph.D.
Executive Chairman
John D. Diekman, Ph.D.
Carl L. Gordon, Ph.D., CFA
Robert Schreiber, Ph.D.
Mike Rothe, Ph.D.
Igenica Management
Robert Schreiber, Ph.D.
Chairman
Rudolf Aebersold, Ph.D.  
Frederick Appelbaum, M.D.  
Thomas Kipps, M.D., Ph.D.  
Richard Klausner, M.D.  
Jeffrey V. Ravetch, M.D., Ph.D.  
Richard Ulevitch, Ph.D.  
Emil Unanue, M.D.  
 
 
 
 
Igenica Leadership

Igenica has assembled a management team with deep operational experience and strong antibody drug discovery expertise.  Supported by a Scientific Advisory Board that comprises key thought leaders in the fields of oncology and immunology and advised by an experienced Board of Directors with a track record of success in the industry, Igenica is well positioned to realize its mission of discovering and developing breakthrough therapeutics for the treatment of cancer.